Related Experiment Videos
Serum prostate-specific antigen in pancreatic disease
R Pezzilli1, A Bertaccini, P Billi
1Emergency Department, University of Bologna, Italy. pezzilli@orsola-malpighi.med.unibo.it
Italian Journal of Gastroenterology and Hepatology
|December 22, 1999
Summary
Detectable serum prostate-specific antigen (PSA) levels were found in some female patients with acute pancreatitis and pancreatic cancer. This finding suggests pancreatic diseases may impact PSA test specificity for prostate cancer detection.
Area of Science:
- Biochemistry
- Oncology
- Gastroenterology
Background:
- Prostate-specific antigen (PSA) is a recognized marker for prostate cancer.
- Emerging evidence suggests PSA presence in pancreatic tissue.
- Limited data exists on serum PSA levels in pancreatic diseases.
Purpose of the Study:
- To investigate the influence of pancreatic diseases on total and free serum PSA levels.
- To assess potential alterations in PSA in patients with pancreatic conditions.
Main Methods:
- Study included 72 females: 44 with acute pancreatitis, 6 with chronic pancreatitis, 12 with pancreatic carcinoma, and 10 healthy controls.
- Total and free serum PSA were quantified using commercial assay kits.
Main Results:
- Detectable total and free PSA were observed in 5% of acute pancreatitis patients.
- PSA was undetectable in chronic pancreatitis patients.
- 33% of pancreatic carcinoma patients showed detectable total and free PSA levels.
Conclusions:
- Female patients with pancreatic cancer, and to a lesser extent acute pancreatitis, can exhibit detectable serum PSA.
- Further research is needed to elucidate the mechanisms behind PSA elevation in pancreatic diseases.
- Elevated PSA in pancreatic disease may compromise its specificity as a prostate cancer biomarker.